Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. - Wikidata - awgldk - TriplyDB

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

http://www.wikidata.org/entity/Q46592677

about

Nuclear Receptor Regulation of Aquaporin-2 in the Kidney Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies The role of transforming growth factor β1 in the regulation of blood pressure Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty Update on the treatment of type 2 diabetes mellitus 'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies Regulation and dysregulation of epithelial Na+ channels Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?Nuclear receptors as drug targets for metabolic disease.Increased renin production in mice with deletion of peroxisome proliferator-activated receptor-gamma in juxtaglomerular cells.Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.The Concise Guide to PHARMACOLOGY 2013/14: ion channels Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.Pharmacotherapy of end-stage renal disease.Relationship between urinary sodium excretion and pioglitazone-induced edema.ERRgamma regulates cardiac, gastric, and renal potassium homeostasis.Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action.Selective Tissue Distribution Mediates Tissue-Dependent PPARγ Activation and Insulin Sensitization by INT131, a Selective PPARγ Modulator.Pharmacophore-driven identification of PPARγ agonists from natural sources.Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.Molecular determinants of the cardiometabolic phenotype.Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors Bioimpedance spectroscopy for the estimation of body fluid volumes in mice Thiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution.Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.The relationship between peroxisome proliferator-activated receptor-gamma and renin: a human genetics study.Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function Screening for bioactive metabolites in plant extracts modulating glucose uptake and fat accumulation Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.PPAR gamma and human metabolic disease Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities

P2860

Q26740554-81A34B15-5A74-447E-8867-9CC41410D6AD Q26851905-A918B0FD-25B8-45FC-8F40-0117ED123673 Q26866958-28EF1182-D002-40E8-8925-7FBBE1C0A966 Q26998564-D0E84087-1A83-4D3D-8D3F-934EF3E1C5D0 Q27003819-78BB081F-D7A7-4D4C-9E2C-6D1BECD49E1F Q27024799-B97EE1B9-9486-4908-814D-D2754438BDF6 Q28073342-B6A20F49-4D82-42A8-B445-BF84173BC276 Q28221639-4EED78B7-8D38-4B7B-BE02-EAF35E14C599 Q28251865-58465CAC-81B5-4DC1-8A57-847A2A121439 Q28540671-58DA462C-6A30-4AFF-AC4C-857C7A7683B0 Q30241952-CE9DDBE5-5E76-4A00-8F02-5F0F44F23B18 Q30353176-9B6D666B-BE78-4694-B505-206AE6EE4D4E Q30430126-228442BC-A388-4027-873E-8F6B4F4DA651 Q30433046-C7D614E9-7B02-4EF7-B953-DCCA0CFCF238 Q30483132-FE66BD5E-3117-4BB0-A69D-B8BD9F3900EE Q30486735-8FCD4063-D980-4100-8E50-41871010DA13 Q30717371-9873C886-3C0E-4B0F-B277-E0F3B0E5F2DD Q33527739-5C5D677C-02B7-4527-A2A0-568B75703408 Q33531889-66F73CA4-3CB8-4268-80B7-941153C51700 Q33609760-450842BD-446C-4A5A-86BB-63B287392794 Q33634214-EB00BE12-86C5-4EB0-9683-E5564F3CD049 Q33637525-0FC3BBE0-911A-4D1B-99C1-221C1C62152A Q33664745-7599B985-E9DA-40C1-A3AA-E2F94C942D1A Q33736617-ABC36B30-A828-43AD-8155-21F398E27665 Q33744181-EA56D6CF-911E-4447-BDF0-D3E155DEE39C Q33782620-01313C27-0BAD-4CB6-BFDB-A9B548D71D4B Q33921392-D9315A9E-BBDC-4C9A-9868-CB5DBCB1BC23 Q33960919-942E3D0D-FE34-4855-8CDD-8D576D720D2C Q33995127-261D950C-025D-4F1E-B2BB-E1A19A4887DC Q34020483-17A4E279-1B43-4D13-9D8F-26BC771E3892 Q34023636-B9965850-AA9D-4838-A64F-946448C80588 Q34113128-D08D3EDB-6273-44B2-8CD6-8A8AA1354A57 Q34123775-14901B85-C8E0-45F6-902B-03D1B85AB865 Q34183013-5595EE9C-3CF6-42DD-84C1-74D63D1033A8 Q34260759-BA0B2BA7-4A26-48C1-A2B3-37657BBCDA14 Q34315432-54492E58-B53F-4CBA-A075-E2349C272B7E Q34416432-31195A19-027B-471E-9AD1-2B93B8E2E934 Q34452976-F29567DF-CFE1-4DDF-810C-9A4B960D0B37 Q34502676-B394682A-20E4-4097-A448-FDB026D5B80E Q34625038-0DF36C49-C377-403D-8083-4193AE3DCD91

P2860

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

http://www.wikidata.org/entity/Q46592677

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Thiazolidinediones expand body ...... ediated renal salt absorption.

@en

Thiazolidinediones expand body ...... ediated renal salt absorption.

@nl

type

label

Thiazolidinediones expand body ...... ediated renal salt absorption.

@en

Thiazolidinediones expand body ...... ediated renal salt absorption.

@nl

prefLabel

Thiazolidinediones expand body ...... ediated renal salt absorption.

@en

Thiazolidinediones expand body ...... ediated renal salt absorption.

@nl

P1433

Q46592677-768F290E-71EE-48A2-8B1C-72668A829A5F

P1476

Q46592677-4E3B1882-CA62-4CC0-BCDE-20B4BC77E94D

P2093

Q46592677-092CFBB7-16E6-486C-81AF-E21888071057

Q46592677-32A002EF-D67A-471A-9AC0-203DE904BB5F

Q46592677-373C5702-E370-48F1-A086-B9C187C4E9A8

Q46592677-4F1D9893-A10C-4882-AA29-895652F06089

Q46592677-8C3D6F35-307D-4CF2-A3DF-96668880D570

Q46592677-9D9817B8-2C1E-433B-AD3E-AEAF0B25E107

Q46592677-CF0AF948-0AA2-4760-A1BB-3A330F4B58A0

Q46592677-D20D2730-D5BF-48FD-BAF8-A4095C064563

Q46592677-E427BC15-3B47-4776-A9F5-44AD795344E6

P2888

Q46592677-06FA990E-6B82-4486-8C22-561618D320D0

P304

Q46592677-9E6B8C57-AF5E-4C6C-8CB7-00DC33B9C8F9

P31

Q46592677-40D51666-0E57-44FE-AC76-3AAB53A74C72

P356

Q46592677-27DDB085-E699-4380-AA16-FA2D3CFF8C97

P407

Q46592677-2EA380C4-6BD0-4C60-A729-03E4CAA499EB

P433

Q46592677-E3430E7C-197D-446A-A5A5-D7B4C2A47E23

P478

Q46592677-4044A02F-3853-44DB-B41F-C25FBBDE430E

P50

Q46592677-38F2CF6C-3203-4EB9-8579-F1E113C65D01

P577

Q46592677-35ABE9A4-8573-4D37-83F0-C44250F779A7

P5875

Q46592677-2B099674-5B94-4CB6-A6B8-8C524ECF8B9A

P6179

Q46592677-725B47B0-A578-4C8B-B6CC-73BC3B15FDCB

P698

Q46592677-AD2C72F0-AB5F-48B6-B417-F61647D28218

P356

P1433

Nature Medicine

P1476

Thiazolidinediones expand body ...... ediated renal salt absorption.

@en

P2093

Chuanming Hao

http://www.w3.org/2001/XMLSchema#string

Dae Ryong Cha

http://www.w3.org/2001/XMLSchema#string

Donald E Kohan

http://www.w3.org/2001/XMLSchema#string

Matthew D Breyer

http://www.w3.org/2001/XMLSchema#string

Reena Rao

http://www.w3.org/2001/XMLSchema#string

Reyadh Redha

http://www.w3.org/2001/XMLSchema#string

Wendell Lu

http://www.w3.org/2001/XMLSchema#string

Yahua Zhang

http://www.w3.org/2001/XMLSchema#string

YouFei Guan

http://www.w3.org/2001/XMLSchema#string

P2888

P304

861-866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1278

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7737645

http://www.w3.org/2001/XMLSchema#string

P6179

1008693114

http://www.w3.org/2001/XMLSchema#string

P698

16007095

http://www.w3.org/2001/XMLSchema#string